R. Hanna

The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.

Dirk E. Smith, A. Farese, T. MacVittie, 2003, Immunity.

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

L. Moreland, W. Koopman, R. Hanna, 1996, The Journal of rheumatology.

A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia

J. Fay, M. Baer, S. Bernstein, 1999, Cancer Chemotherapy and Pharmacology.

Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor.

M. Peters, R. Hanna, C. Jacobs, 1994, Journal of immunology.

The pharmacokinetics of etanercept in patients with heart failure.

D. Mann, A. Feldman, V. M. Schneider, 2001, British journal of clinical pharmacology.

The Pharmacokinetics of Etanercept in Healthy Volunteers

D. Simcoe, J. Korth-Bradley, R. Hanna, 2000, The Annals of pharmacotherapy.

Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy

W. Meyer, W. Furman, C. Pratt, 1997, Cancer Chemotherapy and Pharmacology.

A comparison of effects on reproduction and neonatal development in cynomolgus monkeys given human soluble IL-4R and mice given murine soluble IL-4R.

A. Hoberman, R. Hanna, S. Oneda, 2009, Regulatory toxicology and pharmacology : RTP.